Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Board overhaul puts governance in focus for Henry Schein (HSIC)
Henry Schein (HSIC) has put governance in the spotlight after announcing that longtime Chairman Stanley M. Bergman will retire and several directors will step down, which will shrink the Board from fifteen to ten members.
See our latest analysis for Henry Schein.
At a share price of US$75.53, Henry Schein has seen short term share price pressure, with a 30 day share price return of a 3.29% decline and a 90 day share price return of a 4.39% decline, even as the 1 year total shareholder return sits at 14.16%. This suggests recent governance headlines are being weighed against a longer record of value creation.
If this governance reshuffle has you thinking about where else capital could work, it may be worth scanning other healthcare names that blend medicine and technology, including 34 healthcare AI stocks .
With an intrinsic value estimate that sits well above the current US$75.53 share price and a value score of 5, the key question is whether Henry Schein still offers a mispriced entry point or if markets already reflect its future growth potential.
Most Popular Narrative: 16.1% Undervalued
With Henry Schein last closing at $75.53 against a narrative fair value of $90, the current governance reset sits against expectations built on measured earnings and margin expansion using a 6.98% discount rate.
The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion.
Want to see what sits behind that mix shift? Revenue, earnings, and margins are all wired into this story, along with a future earnings multiple that has to line up with those cash flows. The full narrative walks through how those pieces connect to the $90 figure.
Result: Fair Value of $90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on execution, and persistent pricing pressure in distribution and any missteps in the leadership transition could quickly challenge that upside story.
Find out about the key risks to this Henry Schein narrative.
Next Steps
If this mix of board change, valuation gap, and execution risk feels finely balanced, act quickly to assess both perspectives by reviewing the 3 key rewards and 2 important warning signs .
Ready for more investment ideas?
If Henry Schein has sharpened your focus, do not stop here, use the Simply Wall St screener to surface focused stock ideas that match your goals.
-
Target value opportunities that combine quality and pricing appeal by checking out 63 high quality undervalued stocks .
-
Prioritise resilience and capital protection by scanning companies in the 72 resilient stocks with low risk scores .
-
Get ahead of the crowd by searching through the screener containing 24 high quality undiscovered gems .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include HSIC .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
